Last updated on April 19, 2014 at 5:20 EDT

Latest Joel Martin Stories

2012-10-17 07:25:42

LA JOLLA, Calif., Oct. 17, 2012 /PRNewswire/ -- Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, today announced results of a Phase 1/2 trial of its lead investigational drug, ERSATTA(TM) in peripheral neuropathy. ERSATTA is the first once-weekly C-peptide therapy to target loss of nerve function and other vascular complications in type 1 diabetes patients. The successful 72 subject trial, which focused on safety, tolerability, and...